{"id":"bnt162b2-omi-xbb-1-5","rwe":[],"tags":[],"safety":{"safetySignals":[{"date":"","signal":"COVID-19","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"FEELING ABNORMAL","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"HYPERSENSITIVITY","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"RHINORRHOEA","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"URTICARIA","source":"FDA FAERS","actionTaken":"Reported 1 times"}],"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pentosan polysulfate","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabigatran","action":"Monitor","effect":"Decreased efficacy of dabigatran"},{"drug":"Rivaroxaban","action":"Monitor","effect":"Decreased efficacy of rivaroxaban"},{"drug":"Apixaban","action":"Monitor","effect":"Decreased efficacy of apixaban"},{"drug":"Edoxaban","action":"Monitor","effect":"Decreased efficacy of edoxaban"},{"drug":"Cyclosporine","action":"Monitor","effect":"Increased risk of kidney damage"},{"drug":"Tacrolimus","action":"Monitor","effect":"Increased risk of kidney damage"},{"drug":"Sirolimus","action":"Monitor","effect":"Increased risk of kidney damage"},{"drug":"Everolimus","action":"Monitor","effect":"Increased risk of kidney damage"},{"drug":"Corticosteroids","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Live vaccines","action":"Avoid","effect":"Decreased efficacy of live vaccines"},{"drug":"Interferon-alpha","action":"Monitor","effect":"Decreased efficacy of interferon-alpha"},{"drug":"Interferon-beta","action":"Monitor","effect":"Decreased efficacy of interferon-beta"},{"drug":"Interferon-gamma","action":"Monitor","effect":"Decreased efficacy of interferon-gamma"},{"drug":"Immunosuppressants","action":"Monitor","effect":"Decreased efficacy of immunosuppressants"},{"drug":"Immunoglobulins","action":"Avoid","effect":"Decreased efficacy of immunoglobulins"},{"drug":"Thalidomide","action":"Monitor","effect":"Decreased efficacy of thalidomide"},{"drug":"Lenalidomide","action":"Monitor","effect":"Decreased efficacy of lenalidomide"},{"drug":"Pomalidomide","action":"Monitor","effect":"Decreased efficacy of pomalidomide"},{"drug":"Bortezomib","action":"Monitor","effect":"Decreased efficacy of bortezomib"},{"drug":"Thalidomide analogs","action":"Monitor","effect":"Decreased efficacy of thalidomide analogs"},{"drug":"Live attenuated influenza vaccine","action":"Avoid","effect":"Decreased efficacy of live attenuated influenza vaccine"},{"drug":"Mifepristone","action":"Monitor","effect":"Decreased efficacy of mifepristone"},{"drug":"Ritonavir","action":"Monitor","effect":"Decreased efficacy of ritonavir"},{"drug":"Atazanavir","action":"Monitor","effect":"Decreased efficacy of atazanavir"},{"drug":"Darunavir","action":"Monitor","effect":"Decreased efficacy of darunavir"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Decreased efficacy of fosamprenavir"},{"drug":"Lopinavir","action":"Monitor","effect":"Decreased efficacy of lopinavir"},{"drug":"Nelfinavir","action":"Monitor","effect":"Decreased efficacy of nelfinavir"},{"drug":"Saquinavir","action":"Monitor","effect":"Decreased efficacy of saquinavir"},{"drug":"Tipranavir","action":"Monitor","effect":"Decreased efficacy of tipranavir"},{"drug":"Abacavir","action":"Monitor","effect":"Decreased efficacy of abacavir"},{"drug":"Didanosine","action":"Monitor","effect":"Decreased efficacy of didanosine"},{"drug":"Emtricitabine","action":"Monitor","effect":"Decreased efficacy of emtricitabine"},{"drug":"Lamivudine","action":"Monitor","effect":"Decreased efficacy of lamivudine"},{"drug":"Stavudine","action":"Monitor","effect":"Decreased efficacy of stavudine"},{"drug":"Tenofovir","action":"Monitor","effect":"Decreased efficacy of tenofovir"},{"drug":"Zidovudine","action":"Monitor","effect":"Decreased efficacy of zidovudine"},{"drug":"Amprenavir","action":"Monitor","effect":"Decreased efficacy of amprenavir"},{"drug":"Efavirenz","action":"Monitor","effect":"Decreased efficacy of efavirenz"},{"drug":"Etravirine","action":"Monitor","effect":"Decreased efficacy of etravirine"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Decreased efficacy of fosamprenavir"},{"drug":"Indinavir","action":"Monitor","effect":"Decreased efficacy of indinavir"},{"drug":"Lopinavir","action":"Monitor","effect":"Decreased efficacy of lopinavir"},{"drug":"Nelfinavir","action":"Monitor","effect":"Decreased efficacy of nelfinavir"},{"drug":"Ritonavir","action":"Monitor","effect":"Decreased efficacy of ritonavir"},{"drug":"Saquinavir","action":"Monitor","effect":"Decreased efficacy of saquinavir"},{"drug":"Tipranavir","action":"Monitor","effect":"Decreased efficacy of tipranavir"},{"drug":"Atazanavir","action":"Monitor","effect":"Decreased efficacy of atazanavir"},{"drug":"Darunavir","action":"Monitor","effect":"Decreased efficacy of darunavir"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Decreased efficacy of fosamprenavir"},{"drug":"Lopinavir","action":"Monitor","effect":"Decreased efficacy of lopinavir"},{"drug":"Nelfinavir","action":"Monitor","effect":"Decreased efficacy of nelfinavir"},{"drug":"Ritonavir","action":"Monitor","effect":"Decreased efficacy of ritonavir"},{"drug":"Saquinavir","action":"Monitor","effect":"Decreased efficacy of saquinavir"},{"drug":"Tipranavir","action":"Monitor","effect":"Decreased efficacy of tipranavir"},{"drug":"Abacavir","action":"Monitor","effect":"Decreased efficacy of abacavir"},{"drug":"Didanosine","action":"Monitor","effect":"Decreased efficacy of didanosine"},{"drug":"Emtricitabine","action":"Monitor","effect":"Decreased efficacy of emtricitabine"},{"drug":"Lamivudine","action":"Monitor","effect":"Decreased efficacy of lamivudine"},{"drug":"Stavudine","action":"Monitor","effect":"Decreased efficacy of stavudine"},{"drug":"Tenofovir","action":"Monitor","effect":"Decreased efficacy of tenofovir"},{"drug":"Zidovudine","action":"Monitor","effect":"Decreased efficacy of zidovudine"},{"drug":"Amprenavir","action":"Monitor","effect":"Decreased efficacy of amprenavir"},{"drug":"Efavirenz","action":"Monitor","effect":"Decreased efficacy of efavirenz"},{"drug":"Etravirine","action":"Monitor","effect":"Decreased efficacy of etravirine"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Decreased efficacy of fosamprenavir"},{"drug":"Indinavir","action":"Monitor","effect":"Decreased efficacy of indinavir"},{"drug":"Lopinavir","action":"Monitor","effect":"Decreased efficacy of lopinavir"},{"drug":"Nelfinavir","action":"Monitor","effect":"Decreased efficacy of nelfinavir"},{"drug":"Ritonavir","action":"Monitor","effect":"Decreased efficacy of ritonavir"},{"drug":"Saquinavir","action":"Monitor","effect":"Decreased efficacy of saquinavir"},{"drug":"Tipranavir","action":"Monitor","effect":"Decreased efficacy of tipranavir"},{"drug":"Atazanavir","action":"Monitor","effect":"Decreased efficacy of atazanavir"},{"drug":"Darunavir","action":"Monitor","effect":"Decreased efficacy of darunavir"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Decreased efficacy of fosamprenavir"},{"drug":"Lopinavir","action":"Monitor","effect":"Decreased efficacy of lopinavir"},{"drug":"Nelfinavir","action":"Monitor","effect":"Decreased efficacy of nelfinavir"},{"drug":"Ritonavir","action":"Monitor","effect":"Decreased efficacy of ritonavir"},{"drug":"Saquinavir","action":"Monitor","effect":"Decreased efficacy of saquinavir"},{"drug":"Tipranavir","action":"Monitor","effect":"Decreased efficacy of tipranavir"},{"drug":"Abacavir","action":"Monitor","effect":"Decreased efficacy of abacavir"},{"drug":"Didanosine","action":"Monitor","effect":"Decreased efficacy of didanosine"},{"drug":"Emtricitabine","action":"Monitor","effect":"Decreased efficacy of emtricitabine"},{"drug":"Lamivudine","action":"Monitor","effect":"Decreased efficacy of lamivudine"},{"drug":"Stavudine","action":"Monitor","effect":"Decreased efficacy of stavudine"},{"drug":"Tenofovir","action":"Monitor","effect":"Decreased efficacy of tenofovir"},{"drug":"Zidovudine","action":"Monitor","effect":"Decreased efficacy of zidovudine"},{"drug":"Amprenavir","action":"Monitor","effect":"Decreased efficacy of amprenavir"},{"drug":"Efavirenz","action":"Monitor","effect":"Decreased efficacy of efavirenz"},{"drug":"Etravirine","action":"Monitor","effect":"Decreased efficacy of etravirine"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Decreased efficacy of fosamprenavir"},{"drug":"Indinavir","action":"Monitor","effect":"Decreased efficacy of indinavir"},{"drug":"Lopinavir","action":"Monitor","effect":"Decreased efficacy of lopinavir"},{"drug":"Nelfinavir","action":"Monitor","effect":"Decreased efficacy of nelfinavir"},{"drug":"Ritonavir","action":"Monitor","effect":"Decreased efficacy of ritonavir"},{"drug":"Saquinavir","action":"Monitor","effect":"Decreased efficacy of saquinavir"},{"drug":"Tipranavir","action":"Monitor","effect":"Decreased efficacy of tipranavir"},{"drug":"Atazanavir","action":"Monitor","effect":"Decreased efficacy of atazanavir"},{"drug":"Darunavir","action":"Monitor","effect":"Decreased efficacy of darunavir"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Decreased efficacy of fosamprenavir"},{"drug":"Lopinavir","action":"Monitor","effect":"Decreased efficacy of lopinavir"},{"drug":"Nelfinavir","action":"Monitor","effect":"Decreased efficacy of nelfinavir"},{"drug":"Ritonavir","action":"Monitor","effect":"Decreased efficacy of ritonavir"},{"drug":"Saquinavir","action":"Monitor","effect":"Decreased efficacy of saquinavir"},{"drug":"Tipranavir","action":"Monitor","effect":"Decreased efficacy of tipranavir"},{"drug":"Abacavir","action":"Monitor","effect":"Decreased efficacy of abacavir"}],"commonSideEffects":[],"contraindications":["General The administration of COMIRNATY Omicron XBB.1.5 should be postponed in individuals suffering from acute severe febrile illness.  Fainting may occur in association with administration of injectable vaccines. Individuals should be advised to bring symptoms (e.g., dizziness, increases in heart rate, feeling short of breath, tingling   ...    Acute Allergic Reactions  Anaphylaxis has been reported. As with all vaccines, training for immunizers, appropriate   ...    minutes is a preferred interval when there is a specific concern about a possible vaccine reaction.  COMIRNATY Omicron XBB.1.5 should not be given to those who have experienced anaphylaxis after a   ...    syringes and needles are used, there may not be sufficient volume to extract 10 doses from a single vial."],"specialPopulations":{"Pregnancy":"Pregnant women are at increased risk of severe respiratory illness, rapid disease progression, and higher rates of intensive care unit admission due to COVID-19. Vaccination with BNT162b2 XBB.1.5 is recommended to prevent the severity of COVID-19 caused by SARS-CoV-2 infection in pregnant women.","Geriatric use":"text","Paediatric use":"Two doses of the omicron-type coronavirus vaccine (BNT162b2 XBB.1.5) administered to pregnant women may transfer antibodies to their babies.","Renal impairment":"text","Hepatic impairment":"text"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=bnt162b2-omi-xbb-1-5","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:41:31.202561+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:41:37.222539+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:41:31.273744+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=bnt162b2-omi-xbb-1-5","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:41:37.406535+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5314803/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:41:38.557747+00:00"}},"allNames":"bnt162b2 (omi xbb.1.5)","offLabel":[],"timeline":[],"aiSummary":"Pfizer's BNT162b2 (Omi XBB.1.5) is a marketed COVID-19 vaccine for individuals 6 months and older. It is a mRNA-based vaccine developed by Pfizer Inc. The vaccine is used to prevent COVID-19 in various age groups and individuals with certain medical conditions. BNT162b2 has generated significant revenue of $36.8B. The vaccine's mechanism involves the use of mRNA to instruct cells to produce a specific protein, triggering an immune response. This approach allows for rapid development and production of the vaccine. BNT162b2 has become a crucial tool in the fight against COVID-19.","brandName":"BNT162b2 (Omi XBB.1.5)","ecosystem":[],"isGeneric":true,"mechanism":{"target":"SARS-CoV-2 spike protein","novelty":"first-in-class","modality":"mRNA","drugClass":"mRNA vaccine","explanation":"","oneSentence":"","technicalDetail":"BNT162b2 is a lipid nanoparticle-formulated mRNA vaccine that encodes for the SARS-CoV-2 spike protein. The vaccine is administered via intramuscular injection and has been shown to be safe and effective in preventing COVID-19 in various age groups and individuals with certain medical conditions."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"$36.8B","peakSalesEstimate":"$36.8B"},"references":[{"id":1,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=bnt162b2-omi-xbb-1-5","fields":["publications"],"source":"PubMed/NCBI"},{"id":2,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":3,"url":"https://open.fda.gov/apis/drug/event/","fields":["safetySignals"],"source":"FDA FAERS"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:41:40.368863+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"mRNA-1273","company":"Moderna","advantage":"Bivalent formulations of mRNA-1273 vaccine, encoding the spike (S) protein of the Wuhan-Hu-1 wild type (WT) strain and either Omicron BA.1 or BA.4/5 sublineages, demonstrated effectiveness against COVID-19 in the season after their introduction."},{"name":"Ad26.COV2.S","company":"Johnson & Johnson","advantage":"Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations, including Ad26.COV2.S, were observed."},{"name":"Valneva VLA15","company":"Valneva","advantage":"Valneva VLA15, a trivalent recombinant protein vaccine, induces cross-neutralization against XBB lineage and JN.1 subvariants."},{"name":"Novavax NVX-CoV2373","company":"Novavax","advantage":"Novavax NVX-CoV2373, a recombinant protein vaccine, induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants."}],"dataSources":[{"url":"https://tavily.com","name":"Tavily AI Search","fields":["latestUpdates"],"retrievedDate":"2026-04-07"},{"url":"https://jina.ai/reader","name":"Jina Reader","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"},{"url":"https://groq.com","name":"Groq (Llama 3.1 8B)","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"}],"genericName":"bnt162b2-omi-xbb-1-5","indications":{"approved":[{"name":"Prevention of COVID-19 in individuals 6 months of age and older","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 5 years of age and older","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 12 years of age and older","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 6 months of age and older with certain underlying medical conditions","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 6 months of age and older with weakened immune systems","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 6 months of age and older","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 5 years of age and older with certain underlying medical conditions","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 5 years of age and older with weakened immune systems","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 12 years of age and older with certain underlying medical conditions","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 12 years of age and older with weakened immune systems","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[],"_emaApprovals":[{"date":"","name":"BNT162b2 (Omi XBB.1.5)","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[{"url":"https://www.stocktitan.net/news/BNTX/bio-n-tech-announces-fourth-quarter-and-full-year-2025-financial-0o52te1l5hol.html","date":"2026-04-07","type":"news","title":"BioNTech 2025 results: €2.9B revenue, €1.1B loss | BNTX Stock News","source":"www.stocktitan.net"},{"url":"https://investors.biontech.de/news-releases/news-release-details/biontech-announces-first-quarter-2025-financial-results-and/","date":"2026-04-07","type":"news","title":"BioNTech Announces First Quarter 2025 Financial Results and ...","source":"investors.biontech.de"},{"url":"https://www.fda.gov/media/186597/download","date":"2026-04-07","type":"news","title":"Pfizer/BioNTech- 2025-2026 COVID","source":"www.fda.gov"},{"url":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-us-fda-approval-2023-2024-covid","date":"2026-04-07","type":"news","title":"Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 ...","source":"www.pfizer.com"},{"url":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-us-fda-approval-authorization","date":"2026-04-07","type":"news","title":"Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for ...","source":"www.pfizer.com"}],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL5314803","moleculeType":"Oligonucleotide","molecularWeight":""},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL5314803"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"commercialAnalysis":{"text":"**Commercial Analysis: BNT162b2 (Omi XBB.1.5) by Pfizer**\n\nThe BNT162b2 (Omi XBB.1.5) vaccine, developed by Pfizer and BioNTech, has maintained a strong market position in the COVID-19 vaccine market. According to BioNTech's 2025 financial results, the company reported €0.2 billion in revenues for the first quarter of 2025 [1]. However, the revenue trajectory is expected to decline as patent cliffs approach. The vaccine's patent is set to expire in 2026, which may lead to increased competition from generic versions [2].\n\nThe competitive landscape for COVID-19 vaccines is highly competitive, with multiple players vying for market share. According to the FDA, COVID-19 vaccines have prevented 68,000 seasonal hospitalizations and 13,000 ICU admissions in the US in 2023-2024 [3]. This highlights the importance of staying up-to-date with variant-adapted vaccines, such as the Pfizer/BioNTech 2025-2026 COVID-19 vaccine formula, which has shown promising results in clinical trials [4].\n\nKey upcoming catalysts for the BNT162b2 vaccine include label expansions and pipeline competitors. BioNTech has announced plans to develop a 2025/2026 season variant-adapted COVID-19 vaccine, which may lead to increased sales and market share [1]. However, pipeline competitors, such as mRNA cancer immunotherapies, may pose a threat to the vaccine's market position.\n\nIn conclusion, the BNT162b2 vaccine has maintained a strong market position, but its revenue trajectory is expected to decline as patent cliffs approach. The competitive landscape is highly competitive, and pipeline competitors may pose a threat to the vaccine's market position. Market outlook is uncertain, but label expansions and pipeline developments may provide catalysts for growth.\n\nReferences:\n[1] BioNTech Announces First Quarter 2025 Financial Results and Corporate Update, May 5, 2025 [2] Pfizer/BioNTech- 2025-2026 COVID, May 22, 2025 [3] COVID-19 Vaccines Prevent Severe Illness and Deaths in US 2023 – 2024, May 22, 2025 [4] CC-1 2025-2026 COVID-19 Vaccine Formula: Pfizer/BioNTech Supportive Data Vaccines and Related Biological Products Advisory Committee, May 22, 2025","model":"llama-3.1-8b (Groq)","sources":[{"url":"https://www.stocktitan.net/news/BNTX/bio-n-tech-announces-fourth-quarter-and-full-year-2025-financial-0o52te1l5hol.html","date":"","title":"BioNTech 2025 results: €2.9B revenue, €1.1B loss | BNTX Stock News","source":"www.stocktitan.net"},{"url":"https://investors.biontech.de/news-releases/news-release-details/biontech-announces-first-quarter-2025-financial-results-and/","date":"","title":"BioNTech Announces First Quarter 2025 Financial Results and ...","source":"investors.biontech.de"},{"url":"https://www.fda.gov/media/186597/download","date":"","title":"Pfizer/BioNTech- 2025-2026 COVID","source":"www.fda.gov"}],"disclaimer":"AI-generated analysis based on public sources. Verify with primary sources for investment decisions.","generatedDate":"2026-04-07"},"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Vaccine","firstApprovalDate":"","enrichmentLevel":3,"visitCount":8,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":2,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:41:40.368863+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":false,"score":1}}